ArticleCureus2026
Initial Experience With Robotic-Assisted Laparoscopic Adrenalectomy in a Tertiary Center: Feasibility, Perioperative Outcomes, and Histopathology.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRobotic-assisted laparoscopic adrenalectomy (RALA) extends minimally invasive adrenal surgery by adding three-dimensional visualization and wristed instrumentation. While laparoscopic adrenalectomy remains the standard approach, real-world perioperative performance of RALA in tertiary referral settings warrants evaluation. We aimed to describe the feasibility, perioperative outcomes, complications, and histopathology of consecutive patients undergoing RALA at our institution. MATERIALS AND
methodsWe conducted a retrospective observational analysis of consecutive patients undergoing RALA at a tertiary referral center (November 2021-November 2024). Demographic, imaging, operative, and pathologic variables were collected. Complications were graded using the Clavien-Dindo system, with patients without events explicitly reported as Grade 0. Analyses were descriptive.
resultsSixteen patients underwent RALA (10/16 (62.5%) male); median age was 63 years (range 40-83). Median radiologic tumor size was 5.03 cm (range 1.2-12.5). All cases were completed without conversion. Median operative time was 147 minutes (range 70-270), and median estimated blood loss was 105 mL (range 20-250). Postoperative morbidity was low: Grade 0 in 15/16 (93.8%) and one Grade II event in 1/16 (6.2%); no Grade I or Grade III-IV events occurred. Median hospital stay was 7.5 days (range 2-44) overall and three days when excluding a prespecified outlier with bilateral disease and significant comorbidity. Because one patient had bilateral surgery, pathology was reported per lesion (n=17): benign 14/17 (82.4%), malignant 2/17 (11.8%), and indeterminate 1/17 (5.9%); malignancy was suspected preoperatively in one lesion and was an incidental final-pathology finding in the second. Intraoperative ultrasonography was used in one complex case to assist localization. DISCUSSION: These findings align with contemporary reports of low morbidity and reliable completion for RALA, with operative metrics and recovery profiles within published ranges. Technical elements such as early adrenal vein control may support hemodynamic stability in hormonally active tumors, and selective intraoperative ultrasonography can aid dissection when anatomy is distorted.
conclusionIn this early institutional series, RALA was feasible and safe, with zero conversions, low blood loss, and very low complication rates, alongside rapid recovery after sensitivity adjustment for a single outlier. Prospective comparative studies are needed to refine patient selection and to evaluate long-term oncologic outcomes and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.